Companies › Myricx Pharma
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MX006 Anti-B7-H3 antibody-drug conjugate | CD276 | Phase 1 | Advanced and/or Metastatic Solid Tumors Known to Express B7-H3 | Jul 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07807241 | MX006 | Phase 1 | Advanced and/or Metastatic Solid Tumors Known to Express B7-H3 | Oncology | Jul 2030 |
Beijing Biotech Hansoh BioMedical R&D Company Innolake Biopharm GSK
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.